Bill
SB 2888
Allows licensed pharmacists to prescribe FDA-approved tobacco cessation therapies to qualified adults, with insurer coverage for these pharmacist-provided services starting 2027.
Title: AN ACT RELATING TO BUSINESSES AND PROFESSIONS -- PHARMACIES
Jurisdiction: Rhode Island | Introduced: March 4, 2026 | Referred to: Senate Health & Human Services
Purpose
- To expand the scope of pharmacist practice to include prescribing and dispensing FDA-approved tobacco cessation drug therapies to qualified patients.
- To require health insurance plans to cover pharmacists’ services, including tobacco cessation therapies, across multiple types of plans and organizations, starting January 1, 2027.
- To integrate pharmacist-provided tobacco cessation services into the broader framework of professional practice and health care delivery, with oversight and guidelines administered by relevant state health authorities.
Key Provisions
1) New prescriptive authority for tobacco cessation (Section 5-19.1-39)
- A licensed pharmacist may prescribe and dispense FDA-approved tobacco cessation drug therapies to a qualified patient.
- Implementation subject to rules/regulations by the Rhode Island Board of Pharmacy, with approval and guidance from the Director of Health (in consultation with the Director of Behavioral Healthcare, Developmental Disabilities and Hospitals).
- Qualified patient criteria:
- 18 years or older (or minimum age per latest FDA guidance).
- Willing to participate in a structured tobacco cessation program, including initial evaluation and follow-up with the prescribing pharmacist.
- Educated on nicotine toxicity, potential adverse effects, and when to seek medical care.
- Pre-prescription requirements:
- Pharmacist must complete tobacco cessation education approved by the Board of Pharmacy.
- Pharmacist must consult/referto a primary care provider for high-risk patients or contraindicated cases.
- Clinical standards:
- Pharmacists must follow updated clinical practice guidelines approved by the Board of Pharmacy, with health department oversight.
- Services include patient education on therapies and cessation strategies, plus referrals to Department of Health resources.
- Care coordination:
- Screening, prescription record, and follow-up care plan must be shared with the patient’s primary care provider within five business days of prescribing.
- Adaptation:
- Definition of “qualified patient” may be updated via Board of Pharmacy regulations (in consultation with Health Department leadership).
2) Insurance coverage for pharmacist services (Sections 27-18-96, 27-19-88, 27-20-84, 27-41-101)
- Effective January 1, 2027, group health plans and related insurance products must provide coverage for pharmacist services within the lawful scope of practice (as defined in 5-19.1-2) if the plan would cover the same service when performed by a physician, advanced practice nurse, or physician assistant.
- No constraints on reimbursement:
- No nonprofit medical service corporation may require supervision, signature, or referral by another provider as a condition of reimbursement.
- No requirement to pay duplicative services if both a pharmacist and another provider rendered services.
- Network adequacy:
- Plans must include an adequate number of pharmacists in their networks of participating medical providers.
- Merely having pharmacies in a plan’s drug benefit does not meet the requirement to include pharmacists in the medical provider network.
- Geographic/network coverage:
- Benefits apply within the insurer’s provider network.
- Plans must provide coverage outside the network if essential services are not available within the network.
3) Effective date
- The act takes effect upon passage.
- Insurance coverage requirements commence on January 1, 2027.
Affected Parties and Impacts
Procedural and Timeline Notes
Overall Assessment
SB 2888 would significantly broaden pharmacists’ role in tobacco cessation by authorizing prescriptive authority for FDA-approved cessation therapies, conditional on education and regulatory frameworks. It also ensures payer coverage for pharmacist-provided services across major insurer types starting in 2027, reinforcing access to cessation support while emphasizing coordination with primary care providers and adherence to updated clinical guidelines.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
